Unknown

Dataset Information

GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans.


ABSTRACT:

Rationale

Sedation, dependence, and abuse liability limit the use of non-selective γ-aminobutyric acid (GABAA) receptor positive modulators for the treatment of anxiety. AZD7325 and AZD6280 are novel, subtype-selective GABAAα2,3 receptor positive modulators with limited sedative effects.

Objectives

The current study aimed to confirm target engagement at GABAA receptors by AZD7325 and AZD6280 in humans and to determine the relationship between exposure, GABAA receptor occupancy, and tolerability.

Method

Two PET studies, using high-resolution research tomography (HRRT) and the radioligand [11C]flumazenil, were performed in 12 subjects at baseline and after administration of single oral doses of AZD7325 (0.2 to 30 mg

SUBMITTER: Jucaite A 

PROVIDER: S-EPMC5263201 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature